Role of high‑sensitivity C‑reactive protein in patients with sarcoma
Open Access
- 30 October 2023
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 26 (6) , 1-10
Abstract
Immunotherapy has shown promising results in lung cancer and melanomas; however, the responses have been poor in patients with sarcoma. Understanding the relationship between the immune system and sarcoma is essential to develop improved immunotherapy approaches. High‑sensitivity C‑reactive protein (hs‑CRP) has been proposed as a prognostic marker in other cancer types; however, to the best of our knowledge, the association between hs‑CRP levels and mortality in patients with sarcoma has not been investigated. The present prospective, non‑randomised, non‑interventional explorative study investigated the prognostic value of hs‑CRP in patients with sarcoma. Patients referred to the sarcoma centre of Aarhus University Hospital (Aarhus, Denmark) were included between April 2014 and December 2020. Clinical data were obtained from the national quality sarcoma database and biomarkers other than hs‑CRP were obtained from the clinical laboratory information system. The study cohort consisted primarily of patients with localised sarcoma. hs‑CRP was significantly higher in patients with bone sarcoma (P=0.022) and soft tissue sarcoma (STS; P<0.001) compared with control patients. For STS, grade III tumours but not metastatic disease were associated with a higher hs‑CRP level (P=0.0001). Elevated hs‑CRP levels were associated with increased overall mortality [hazard ratio (HR), 1.91; 95% CI, 1.33‑2.75; P=0.001]. Furthermore, elevated hs‑CRP levels were also associated with decreased progression‑free survival (HR, 1.64; 95% CI, 1.17‑2.29; P=0.004). Furthermore, for patients with hs‑CRP <8 mg/l, higher hs‑CRP was associated with an increased risk of recurrent disease and reduced overall survival compared with those of patients with low hs‑CRP. In conclusion, the present study demonstrated that hs‑CRP was a prognostic factor for overall mortality and progression‑free survival in patients with localised sarcoma at the time of diagnosis. Further studies are required to investigate the mechanism behind the association between hs‑CRP and sarcoma prognosis and its potential use in clinical practice.Keywords
This publication has 33 references indexed in Scilit:
- Pravastatin inhibits C-reactive protein generation induced by fibrinogen, fibrin and FDP in isolated rat vascular smooth muscle cellsInflammation Research, 2011
- Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's diseaseGut, 2011
- Clinical significance of pretreatment serum C‐reactive protein level in soft tissue sarcomaCancer, 2011
- Atorvastatin reduces lipopolysaccharide-induced expression of C-reactive protein in human lung epithelial cellsMolecular Medicine Reports, 2011
- Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcomaInternational Orthopaedics, 2011
- Inflammation and cancer: How hot is the link?Biochemical Pharmacology, 2006
- Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle CellsCirculation, 2003
- Inflammation and cancerNature, 2002
- The C-reactive proteinThe Journal of Emergency Medicine, 1999
- A Review on the Biological Properties of C-Reactive ProteinImmunobiology, 1991